Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study
Conclusions:
Disturbances in potassium balance upon treatment with either olmesartan or enalapril are frequent and without differences between groups. The follow-up of these patients should include control of potassium levels, at least after the first week and the first and second month after initiating treatment.Trial registration: The trial EudraCT "2008-002191-98".
Source: BMC Research Notes - Category: Research Authors: Eugenia EspinelJorge JovenIván GilPilar SuñéBerta RenedoJoan FortDaniel Serón Source Type: research
More News: Chronic Kidney Disease | Enalapril | Nutrition | Research | Statistics | Study | Urology & Nephrology